echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first domestically produced COVID-19 neutralizing antibody combination therapy was approved by the National Food and Drug Administration

    The first domestically produced COVID-19 neutralizing antibody combination therapy was approved by the National Food and Drug Administration

    • Last Update: 2021-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 8, the State Food and Drug Administration urgently approved Tengsheng Huachuang Medical Technology (Beijing) Co.
    , Ltd.
    's new coronavirus neutralizing antibody combined therapy drug Ambavirimab injection (BRII-196) and Romisvirimab injection Liquid (BRII-198) registration application
    .
    This is China's first approved new coronavirus neutralizing antibody combination therapy with independent intellectual property rights
    .
    It is reported that the State Food and Drug Administration, in accordance with the relevant provisions of the Drug Administration Law, in accordance with the special drug approval procedures, conducts emergency review and approval, and approves the above two drugs to be used in combination to treat mild and common types with progress to severe (including hospitalization or Death) Adults and adolescents (12-17 years old, weight ≥40kg) with high-risk factors, patients with novel coronavirus infection (COVID-19)
    .
    Among them, adolescents (12-17 years old, weight ≥40kg) indication population are conditional approval
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.